Influence of DNA damage and repair upon the risk of treatment related leukemia

References

• Smith S M, Le Beau M M, Huo D, Karrison T, Sobecks R M, Anastasi J, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003; 102: 43–52
   PubMed Web of Science ®Google Scholar
• Qian Z, Fernald A A, Godley L A, Larson R A, Le Beau M M. Expression profiling of CD34+ hematopoietic stem/progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia. Proc Natl Acad Sci USA 2002; 99: 14925–14930
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J, Christiansen D H, Desta F, Andersen M K. Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2006; 20: 1943–1949
   PubMed Web of Science ®Google Scholar
• Leone G, Voso M T, Sica S, Morosetti R, Pagano L. Therapy related leukemias: susceptibility, prevention and treatment. Leuk Lymphoma 2001; 41: 255–276
   PubMed Web of Science ®Google Scholar
• Rund D, Ben-Yehuda D. Therapy-related leukemia and myelodysplasia: evolving concepts of pathogenesis and treatment. Hematology 2004; 9: 179–187
   PubMedGoogle Scholar
• Turker A, Guler N. Therapy related acute myeloid leukemia after exposure to 5-fluorouracil: a case report. Hematol Cell Ther 1999; 41: 195–196
   PubMedGoogle Scholar
• Tam C S, Seymour J F, Prince H M, Kenealy M, Wolf M, Januszewicz E H, Westerman D. Treatment-related myelodysplasia following fludarabine combination chemotherapy. Haematologica 2006; 91: 1546–1550
   PubMed Web of Science ®Google Scholar
• Khan S G, Muniz-Medina V, Shahlavi T, Baker C C, Inui H, Ueda T, Emmert S, Schneider T D, Kraemer K H. The human XPC DNA repair gene: arrangement, splice site information content and influence of a single nucleotide polymorphism in a splice acceptor site on alternative splicing and function. Nucleic Acids Res 2002; 30: 3624–3631
   PubMed Web of Science ®Google Scholar
• Vaish M. Mismatch repair deficiencies transforming stem cells into cancer stem cells and therapeutic implications. Mol Cancer 2007; 6: 26
   PubMed Web of Science ®Google Scholar
• Rai R, Peng G, Li K, Lin S Y. DNA damage response: the players, the network and the role in tumor suppression. Cancer Genomics Proteomics 2007; 4: 99–106
   PubMedGoogle Scholar
• Reese J S, Liu L, Gerson S L. Repopulating defect of mismatch repair-deficient hematopoietic stem cells. Blood 2003; 102: 1626–1633
   PubMed Web of Science ®Google Scholar
• Grossman L, Matanoski G, Farmer E, Hedayati M, Ray S, Trock B, . DNA repair as a susceptibility factor in chronic diseases in human populations. Advances in DNA Damage and Repair, E. DMKA, et al. Kluwer Academic/Plenum Publishers, New York 1999; 149–167
   Google Scholar
• Wood R D, Mitchell M, Lindahl T. Human DNA repair genes, 2005. Mutat Res 2005; 577: 275–283
   PubMed Web of Science ®Google Scholar
• Chaney S G, Sancar A. DNA repair: enzymatic mechanisms and relevance to drug response. J Natl Cancer Inst 1996; 88: 1346–1360
   PubMedGoogle Scholar
• Spry M, Scott T, Pierce H, D'Orazio J A. DNA repair pathways and hereditary cancer susceptibility syndromes. Front Biosci 2007; 12: 4191–4207
   PubMed Web of Science ®Google Scholar
• Squire J A, Whitmore G F, Phillips R A. Genetic basis of cancer. The Basic Science of Oncology, I F Tannock, I Tannock, R P Hill. McGraw-Hill Press, New York 1998; 48–78
   Google Scholar
• Iliakis G, Wang H, Perrault A R, Boecker W, Rosidi B, Windhofer F, et al. Mechanisms of DNA double strand break repair and chromosome aberration formation. Cytogenet Genome Res 2004; 104: 14–20
   PubMed Web of Science ®Google Scholar
• Chu G. Double strand break repair. J Biol Chem 1997; 272: 24097–24100
   PubMed Web of Science ®Google Scholar
• Goode E L, Ulrich C M, Potter J D. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 2002; 11: 1513–1530
   PubMed Web of Science ®Google Scholar
• Rothkamm K, Kruger I, Thompson L H, Lobrich M. Pathways of DNA double-strand break repair during the mammalian cell cycle. Mol Cell Biol 2003; 23: 5706–5715
   PubMed Web of Science ®Google Scholar
• Dai Y, Kysela B, Hanakahi L A, Manolis K, Riballo E, Stumm M, et al. Nonhomologous end joining and V(D)J recombination require an additional factor. Proc Natl Acad Sci USA 2003; 100: 2462–2467
   PubMed Web of Science ®Google Scholar
• Arnaudeau C, Lundin C, Helleday T. DNA double-strand breaks associated with replication forks are predominantly repaired by homologous recombination involving an exchange mechanism in mammalian cells. J Mol Biol 2001; 307: 1235–1245
   PubMed Web of Science ®Google Scholar
• Hortobagyi G N. Anthracyclines in the treatment of cancer. An overview. Drugs 1997; 54(Suppl 4)1–7
   PubMed Web of Science ®Google Scholar
• Felix C A. Secondary leukemias induced by topoisomerase-targeted drugs. Biochim Biophys Acta 1998; 1400: 233–255
   PubMed Web of Science ®Google Scholar
• Pfeiffer P, Goedecke W, Obe G. Mechanisms of DNA double-strand break repair and their potential to induce chromosomal aberrations. Mutagenesis 2000; 15: 289–302
   PubMed Web of Science ®Google Scholar
• Larsen A K, Escargueil A E, Skladanowski A. From DNA damage to G2 arrest: the many roles of topoisomerase II. Prog Cell Cycle Res 2003; 5: 295–300
   Google Scholar
• Lovett B D, Strumberg D, Blair I A, Pang S, Burden D A, Megonigal M D, et al. Etoposide metabolites enhance DNA topoisomerase II cleavage near leukemia-associated MLL translocation breakpoints. Biochemistry 2001; 40: 1159–1170
   PubMed Web of Science ®Google Scholar
• Stanulla M, Wang J, Chervinsky D S, Aplan P D. Topoisomerase II inhibitors induce DNA double-strand breaks at a specific site within the AML1 locus. Leukemia 1997; 11: 490–496
   PubMed Web of Science ®Google Scholar
• Mistry A R, Felix C A, Whitmarsh R J, Mason A, Reiter A, Cassinat B, et al. DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N Engl J Med 2005; 352: 1529–1538
   PubMed Web of Science ®Google Scholar
• Nishiyama M, Arai Y, Tsunematsu Y, Kobayashi H, Asami K, Yabe M, et al. 11p15 translocations involving the NUP98 gene in childhood therapy-related acute myeloid leukemia/myelodysplastic syndrome. Genes Chromosomes Cancer 1999; 26: 215–220
   PubMed Web of Science ®Google Scholar
• Strissel P L, Strick R, Rowley J D, Zeleznik-Le N J. An in vivo topoisomerase II cleavage site and a DNase I hypersensitive site colocalize near exon 9 in the MLL breakpoint cluster region. Blood 1998; 92: 3793–3803
   PubMed Web of Science ®Google Scholar
• Tewey K M, Chen G L, Nelson E M, Liu L F. Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 1984; 259: 9182–9187
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J. Insights into leukemogenesis from therapy-related leukemia. N Engl J Med 2005; 352: 1591–1594
   PubMed Web of Science ®Google Scholar
• Beranek D T, Weis C C, Swenson D H. A comprehensive quantitative analysis of methylated and ethylated DNA using high pressure liquid chromatography. Carcinogenesis 1980; 1: 595–606
   PubMed Web of Science ®Google Scholar
• Engelward B P, Allan J M, Dreslin A J, Kelly J D, Wu M M, Gold B, Samson L D. A chemical and genetic approach together define the biological consequences of 3-methyladenine lesions in the mammalian genome. J Biol Chem 1998; 273: 5412–5418
   PubMed Web of Science ®Google Scholar
• Liu L, Nakatsuru Y, Gerson S L. Base excision repair as a therapeutic target in colon cancer. Clin Cancer Res 2002; 8: 2985–2991
   PubMed Web of Science ®Google Scholar
• Chen F X, Zhang Y, Church K M, Bodell W J, Gold B. DNA crosslinking, sister chromatid exchange and cytotoxicity of N-2-chloroethylnitrosoureas tethered to minor groove binding peptides. Carcinogenesis 1993; 14: 935–940
   PubMed Web of Science ®Google Scholar
• Ludlum D B. DNA alkylation by the haloethylnitrosoureas: nature of modifications produced and their enzymatic repair or removal. Mutat Res 1990; 233: 117–126
   PubMed Web of Science ®Google Scholar
• Curtis R E, Boice J D, Jr, Stovall M, Bernstein L, Greenberg R S, Flannery J T, et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 1992; 326: 1745–1751
   PubMed Web of Science ®Google Scholar
• Povirk L F, Shuker D E. DNA damage and mutagenesis induced by nitrogen mustards. Mutat Res 1994; 318: 205–226
   PubMed Web of Science ®Google Scholar
• Hansson J, Lewensohn R, Ringborg U, Nilsson B. Formation and removal of DNA cross-links induced by melphalan and nitrogen mustard in relation to drug-induced cytotoxicity in human melanoma cells. Cancer Res 1987; 47: 2631–2637
   PubMed Web of Science ®Google Scholar
• Worrillow L J, Allan J M. Deregulation of homologous recombination DNA repair in alkylating agent-treated stem cell clones: a possible role in the aetiology of chemotherapy-induced leukaemia. Oncogene 2006; 25: 1709–1720
   PubMed Web of Science ®Google Scholar
• Mamuris Z, Prieur M, Dutrillaux B, Aurias A. The chemotherapeutic drug melphalan induces breakage of chromosomes regions rearranged in secondary leukemia. Cancer Genet Cytogenet 1989; 37: 65–77
   PubMed Web of Science ®Google Scholar
• Andersen M K, Christiansen D H, Pedersen-Bjergaard J. Centromeric breakage and highly rearranged chromosome derivatives associated with mutations of TP53 are common in therapy-related MDS and AML after therapy with alkylating agents: an M-FISH study. Genes Chromosomes Cancer 2005; 42: 358–371
   PubMed Web of Science ®Google Scholar
• Lessard M, Herry A, Berthou C, Leglise M C, Abgrall J F, Morice P, et al. FISH investigation of 5q and 7q deletions in MDS/AML reveals hidden translocations, insertions and fragmentations of the same chromosomes. Leuk Res 1998; 22: 303–312
   PubMed Web of Science ®Google Scholar
• Agarwal S, Tafel A A, Kanaar R. DNA double-strand break repair and chromosome translocations. DNA Repair (Amst) 2006; 5: 1075–1081
   PubMed Web of Science ®Google Scholar
• Drablos F, Feyzi E, Aas P A, Vaagbo C B, Kavli B, Bratlie M S, Pena-Diaz J, Otterlei M, Slupphaug G, Krokan H E. Alkylation damage in DNA and RNA—repair mechanisms and medical significance. DNA Repair (Amst) 2004; 3: 1389–1407
   PubMed Web of Science ®Google Scholar
• Kobune M, Xu Y, Baum C, Kelley M R, Williams D A. Retrovirus-mediated expression of the base excision repair proteins, formamidopyrimidine DNA glycosylase or human oxoguanine DNA glycosylase, protects hematopoietic cells from N,N′,N″-triethylenethiophosphoramide (thioTEPA)-induced toxicity in vitro and in vivo. Cancer Res 2001; 61: 5116–5125
   PubMed Web of Science ®Google Scholar
• Bol S A, van Steeg H, van Oostrom C T, Tates A D, Vrieling H, de Groot A J, et al. Nucleotide excision repair modulates the cytotoxic and mutagenic effects of N-n-butyl-N-nitrosourea in cultured mammalian cells as well as in mouse splenocytes in vivo. Mutagenesis 1999; 14: 317–322
   PubMed Web of Science ®Google Scholar
• Krokan H E, Nilsen H, Skorpen F, Otterlei M, Slupphaug G. Base excision repair of DNA in mammalian cells. FEBS Lett 2000; 476: 73–77
   PubMed Web of Science ®Google Scholar
• Ye N, Holmquist G P, O'Connor T R. Heterogeneous repair of N-methylpurines at the nucleotide level in normal human cells. J Mol Biol 1998; 284: 269–285
   PubMed Web of Science ®Google Scholar
• Cabral Neto J B, Cabral R E, Margot A, Le Page F, Sarasin A, Gentil A. Coding properties of a unique apurinic/apyrimidinic site replicated in mammalian cells. J Mol Biol 1994; 240: 416–420
   PubMed Web of Science ®Google Scholar
• Karran P, Offman J, Bignami M. Human mismatch repair, drug-induced DNA damage, and secondary cancer. Biochimie 2003; 85: 1149–1160
   PubMed Web of Science ®Google Scholar
• Seedhouse C, Russell N. Advances in the understanding of susceptibility to treatment-related acute myeloid leukaemia. Br J Haematol 2007; 137: 513–529
   PubMed Web of Science ®Google Scholar
• Casorelli I, Offman J, Mele L, Pagano L, Sica S, D'Errico M, et al. Drug treatment in the development of mismatch repair defective acute leukemia and myelodysplastic syndrome. DNA Repair (Amst) 2003; 2: 547–559
   PubMed Web of Science ®Google Scholar
• Ben-Yehuda D, Krichevsky S, Caspi O, Rund D, Polliack A, Abeliovich D, et al. Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood 1996; 88: 4296–4303
   PubMed Web of Science ®Google Scholar
• Sheikhha M H, Tobal K, Liu Yin J A. High level of microsatellite instability but not hypermethylation of mismatch repair genes in therapy-related and secondary acute myeloid leukaemia and myelodysplastic syndrome. Br J Haematol 2002; 117: 359–365
   PubMed Web of Science ®Google Scholar
• Baumann P, Benson F E, West S C. Human Rad51 protein promotes ATP-dependent homologous pairing and strand transfer reactions in vitro. Cell 1996; 87: 757–766
   PubMed Web of Science ®Google Scholar
• Bishop D K, Ear U, Bhattacharyya A, Calderone C, Beckett M, Weichselbaum R R, et al. Xrcc3 is required for assembly of Rad51 complexes in vivo. J Biol Chem 1998; 273: 21482–21488
   PubMed Web of Science ®Google Scholar
• Wiese C, Collins D W, Albala J S, Thompson L H, Kronenberg A, Schild D. Interactions involving the Rad51 paralogs Rad51C and XRCC3 in human cells. Nucleic Acids Res 2002; 30: 1001–1008
   PubMed Web of Science ®Google Scholar
• Sonoda E, Sasaki M S, Buerstedde J M, Bezzubova O, Shinohara A, Ogawa H, et al. Rad51-deficient vertebrate cells accumulate chromosomal breaks prior to cell death. EMBO J 1998; 17: 598–608
   PubMed Web of Science ®Google Scholar
• Tebbs R S, Zhao Y, Tucker J D, Scheerer J B, Siciliano M J, Hwang M, et al. Correction of chromosomal instability and sensitivity to diverse mutagens by a cloned cDNA of the XRCC3 DNA repair gene. Proc Natl Acad Sci USA 1995; 92: 6354–6358
   PubMed Web of Science ®Google Scholar
• Seedhouse C, Faulkner R, Ashraf N, Das-Gupta E, Russell N. Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemia. Clin Cancer Res 2004; 10: 2675–2680
   PubMed Web of Science ®Google Scholar
• Brem R, Hall J. XRCC1 is required for DNA single-strand break repair in human cells. Nucleic Acids Res 2005; 33: 2512–2520
   PubMed Web of Science ®Google Scholar
• Seedhouse C, Bainton R, Lewis M, Harding A, Russell N, Das-Gupta E. The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia. Blood 2002; 100: 3761–3766
   PubMed Web of Science ®Google Scholar
• Allan J M, Smith A G, Wheatley K, Hills R K, Travis L B, Hill D A, Swirsky D M, Morgan G J, Wild C P. Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood 2004; 104: 3872–3877
   PubMed Web of Science ®Google Scholar
• Smith A G, Worrillow L J, Allan J M. A common genetic variant in XPD associates with risk of 5q- and 7q-deleted acute myeloid leukemia. Blood 2007; 109: 1233–1236
   PubMed Web of Science ®Google Scholar
• Worrillow L J, Travis L B, Smith A G, Rollinson S, Smith A J, Wild C P, et al. An intron splice acceptor polymorphism in hMSH2 and risk of leukemia after treatment with chemotherapeutic alkylating agents. Clin Cancer Res 2003; 9: 3012–3020
   PubMed Web of Science ®Google Scholar
• Zink D, Mayr C, Janz C, Wiesmuller L. Association of p53 and MSH2 with recombinative repair complexes during S phase. Oncogene 2002; 21: 4788–4800
   PubMed Web of Science ®Google Scholar
• Alani E, Lee S, Kane M F, Griffith J, Kolodner R D. Saccharomyces cerevisiae MSH2, a mispaired base recognition protein, also recognizes Holliday junctions in DNA. J Mol Biol 1997; 265: 289–301
   PubMed Web of Science ®Google Scholar
• Kelly K M, Perentesis J P. Polymorphisms of drug metabolizing enzymes and markers of genotoxicity to identify patients with Hodgkin's lymphoma at risk of treatment-related complications. Ann Oncol 2002; 13(Suppl 1)34–39
   PubMed Web of Science ®Google Scholar
• Allan J M, Wild C P, Rollinson S, Willett E V, Moorman A V, Dovey G J, Roddam P L, Roman E, Cartwright R A, Morgan G J. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc Natl Acad Sci USA 2001; 98: 11592–11597
   PubMed Web of Science ®Google Scholar
• Larson R A, Wang Y, Banerjee M, Wiemels J, Hartford C, Le Beau M M, et al. Prevalence of the inactivating 609C → T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood 1999; 94: 803–807
   PubMed Web of Science ®Google Scholar
• Felix C A, Walker A H, Lange B J, Williams T M, Winick N J, Cheung N K, Lovett B D, Nowell P C, Blair I A, Rebbeck T R. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci USA 1998; 95: 13176–13181
   PubMed Web of Science ®Google Scholar
• Rund D, Krichevsky S, Bar-Cohen S, Goldschmidt N, Kedmi M, Malik E, et al. Therapy-related leukemia: clinical characteristics and analysis of new molecular risk factors in 96 adult patients. Leukemia 2005; 19: 1919–1928
   PubMed Web of Science ®Google Scholar
• Blanco J G, Edick M J, Hancock M L, Winick N J, Dervieux T, Amylon M D, et al. Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies. Pharmacogenetics 2002; 12: 605–611
   PubMedGoogle Scholar
• Bolufer P, Collado M, Barragan E, Calasanz M J, Colomer D, Tormo M, et al. Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia. Br J Haematol 2007; 136: 590–596
   PubMed Web of Science ®Google Scholar
• Naoe T, Takeyama K, Yokozawa T, Kiyoi H, Seto M, Uike N, et al. Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/myelodysplastic syndrome and de novo acute myeloid leukemia. Clin Cancer Res 2000; 6: 4091–4095
   PubMed Web of Science ®Google Scholar
• Hayes J D, Pulford D J. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995; 30: 445–600
   PubMed Web of Science ®Google Scholar
• Sasai Y, Horiike S, Misawa S, Kaneko H, Kobayashi M, Fujii H, et al. Genotype of glutathione S-transferase and other genetic configurations in myelodysplasia. Leuk Res 1999; 23: 975–981
   PubMed Web of Science ®Google Scholar
• Woo M H, Shuster J J, Chen C, Bash R O, Behm F G, Camitta B, Felix C A, et al. Glutathione S-transferase genotypes in children who develop treatment-related acute myeloid malignancies. Leukemia 2000; 14: 232–237
   PubMed Web of Science ®Google Scholar
• Davies S M, Robison L L, Buckley J D, Tjoa T, Woods W G, Radloff G A, et al. Glutathione S-transferase polymorphisms and outcome of chemotherapy in childhood acute myeloid leukemia. J Clin Oncol 2001; 19: 1279–1287
   PubMed Web of Science ®Google Scholar
• Jackson S P. Sensing and repairing DNA double-strand breaks. Carcinogenesis 2002; 23: 687–696
   PubMed Web of Science ®Google Scholar
• Sandoval A, Consoli U, Plunkett W. Fludarabine-mediated inhibition of nucleotide excision repair induces apoptosis in quiescent human lymphocytes. Clin Cancer Res 1996; 2: 1731–1741
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Nowak B J, Keating M J, Plunkett W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res 2001; 7: 3580–3589
   PubMed Web of Science ®Google Scholar
• Li L, Liu X, Glassman A B, Keating M J, Stros M, Plunkett W, et al. Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA adducts in vitro. Cancer Res 1997; 57: 1487–1494
   PubMed Web of Science ®Google Scholar
• de Vries J F, Falkenburg J H, Willemze R, Barge R M. The mechanisms of Ara-C-induced apoptosis of resting B-chronic lymphocytic leukemia cells. Haematologica 2006; 91: 912–919
   PubMed Web of Science ®Google Scholar
• Kufe D W, Major P P, Egan E M, Beardsley G P. Correlation of cytotoxicity with incorporation of ara-C into DNA. J Biol Chem 1980; 255: 8997–8900
   PubMed Web of Science ®Google Scholar
• O'Byrne K J, Philip P A, Propper D J, Braybrooke J P, Saunders M P, Bates N P, et al. A phase II study of the modulation of 5-fluorouracil and folinic acid with high-dose infusional hydroxyurea in metastatic colorectal carcinoma. Ann Oncol 1999; 10: 981–983
   PubMed Web of Science ®Google Scholar
• Wollman M R, Penchansky L, Shekhter-Levin S. Transient 7q- in association with megaloblastic anemia due to dietary folate and vitamin B12 deficiency. J Pediatr Hematol Oncol 1996; 18: 162–165
   PubMed Web of Science ®Google Scholar
• Eto I, Krumdieck C L. Role of vitamin B12 and folate deficiencies in carcinogenesis. Adv Exp Med Biol 1986; 206: 313–330
   PubMedGoogle Scholar
• Robien K, Ulrich C M. 5,10-Methylenetetrahydrofolate reductase polymorphisms and leukemia risk: a HuGE minireview. Am J Epidemiol 2003; 157: 571–582
   PubMed Web of Science ®Google Scholar
• Branda R F, Hacker M, Lafayette A, Nigels E, Sullivan L, Nicklas J A, et al. Nutritional folate deficiency augments the in vivo mutagenic and lymphocytotoxic activities of alkylating agents. Environ Mol Mutagen 1998; 32: 33–38
   PubMed Web of Science ®Google Scholar
• Branda R F, Blickensderfer D B. Folate deficiency increases genetic damage caused by alkylating agents and gamma-irradiation in Chinese hamster ovary cells. Cancer Res 1993; 53: 5401–5408
   PubMed Web of Science ®Google Scholar
• Holden S A, Teicher B A, Robinson M F, Northey D, Rosowsky A. Antifolates can potentiate topoisomerase II inhibitors in vitro and in vivo. Cancer Chemother Pharmacol 1995; 36: 165–171
   PubMed Web of Science ®Google Scholar
• Shapiro S, Hughes G, Al-Obaidi M J, O'Reilly E, Ramesh S, Smith J, et al. Acute myeloid leukaemia secondary to treatment with capecitabine for metastatic colorectal cancer. Eur J Haematol 2007; 78: 543–544
   PubMed Web of Science ®Google Scholar
• Linassier C, Barin C, Calais G, Letortorec S, Bremond J L, Delain M, et al. Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy. Ann Oncol 2000; 11: 1289–1294
   PubMed Web of Science ®Google Scholar
• de Jonge R, Hooijberg J H, van Zelst B D, Jansen G, van Zantwijk C H, Kaspers G J, et al. Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia. Blood 2005; 106: 717–720
   PubMed Web of Science ®Google Scholar
• Etienne M C, Formento J L, Chazal M, Francoual M, Magne N, Formento P, et al. Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics 2004; 14: 785–792
   PubMedGoogle Scholar
• Frosst P, Blom H J, Milos R, Goyette P, Sheppard C A, Matthews R G, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111–113
   PubMed Web of Science ®Google Scholar
• Weisberg I S, Jacques P F, Selhub J, Bostom A G, Chen Z, Curtis Ellison R, et al. The 1298A → C polymorphism in methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association with homocysteine. Atherosclerosis 2001; 156: 409–415
   PubMed Web of Science ®Google Scholar
• Lievers K J, Boers G H, Verhoef P, den Heijer M, Kluijtmans L A, van der Put N M, et al. A second common variant in the methylenetetrahydrofolate reductase (MTHFR) gene and its relationship to MTHFR enzyme activity, homocysteine, and cardiovascular disease risk. J Mol Med 2001; 79: 522–528
   PubMed Web of Science ®Google Scholar
• Sohn K J, Croxford R, Yates Z, Lucock M, Kim Y I. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst 2004; 96: 134–144
   PubMed Web of Science ®Google Scholar
• Jakobsen A, Nielsen J N, Gyldenkerne N, Lindeberg J. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 2005; 23: 1365–1369
   PubMed Web of Science ®Google Scholar
• Shrubsole M J, Shu X O, Ruan Z X, Cai Q, Cai H, Niu Q, et al. MTHFR genotypes and breast cancer survival after surgery and chemotherapy: a report from the Shanghai Breast Cancer Study. Breast Cancer Res Treat 2005; 91: 73–79
   PubMed Web of Science ®Google Scholar
• Guillem V M, Collado M, Terol M J, Calasanz M J, Esteve J, Gonzalez M, et al. Role of MTHFR (677, 1298) haplotype in the risk of developing secondary leukemia after treatment of breast cancer and hematological malignancies. Leukemia 2007; 21: 1413–1422
   PubMed Web of Science ®Google Scholar
• Stam R W, Hubeek I, den Boer M L, Buijs-Gladdines J G, Creutzig U, Kaspers G J, et al. MLL gene rearrangements have no direct impact on Ara-C sensitivity in infant acute lymphoblastic leukemia and childhood M4/M5 acute myeloid leukemia. Leukemia 2006; 20: 179–182
   PubMed Web of Science ®Google Scholar
• Huang Y, Fang Y, Wu J, Dziadyk J M, Zhu X, Sui M, et al. Regulation of Vinca alkaloid-induced apoptosis by NF-kappaB/IkappaB pathway in human tumor cells. Mol Cancer Ther 2004; 3: 271–277
   PubMed Web of Science ®Google Scholar
• Pickell L, Tran P, Leclerc D, Hiscott J, Rozen R. Regulatory studies of murine methylenetetrahydrofolate reductase reveal two major promoters and NF-kappaB sensitivity. Biochim Biophys Acta 2005; 1731: 104–114
   PubMed Web of Science ®Google Scholar
• Collado M, Barragan E, Bolufer P, Calasanz M J, Larrayoz M J, Colomer D, et al. Lack of association of CYP3A4-V polymorphism with the risk of treatment-related leukemia. Leuk Res 2005; 29: 595–597
   PubMed Web of Science ®Google Scholar
• Hake C R, Graubert T A, Fenske T S. Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients?. Bone Marrow Transplant 2007; 39: 59–70
   PubMed Web of Science ®Google Scholar